AstraZeneca Pharma India and Sun Pharmaceutical Industries have announced a second brand partnership to expand the availability of sodium zirconium cyclosilicate (SZC) across India. This exclusive collaboration aims to accelerate patient access to this innovative and effective therapy for hyperkalaemia.
Under the partnership, both companies will market and distribute SZC under separate brand names. AstraZeneca will continue to market the product as Lokelma, while Sun Pharma will promote it under the brand Gimliand. AstraZeneca will retain intellectual property rights and hold both the marketing authorization and import license for the molecule.
Hyperkalaemia remains a critical clinical issue, especially among individuals with chronic kidney disease or heart failure who are on RAAS inhibitor therapy and therefore at higher risk of elevated potassium levels.
With Sun Pharma’s strong market leadership in India and AstraZeneca’s focus on advancing science-driven care, the partnership is expected to significantly improve the availability of SZC nationwide and support better patient outcomes.
Also Read